Although we demonstrated a predictive and prognostic value of EGFR/TP53 co-mutations in a small cohort of NSCLC, future validation using a similar cohort with a large set of patients is needed to corroborate the observed correlations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.